Psychiatr. pro Praxi, 2006; 6: 268-271

DOSING OF ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA

MUDr. Sylva Racková, MUDr. Luboš Janů Ph.D
Psychiatrická klinika FN a LF UK v Plzni

Schizophrenia is a serious disorder with the beginning especially in the adolescent and early adult ages. There is a high percentage of chronic course in this disorder. Long-term antipsychotic medication is necessary in the treatment, first in the treatment of acute state and then in the profylaxis of relapses. During the treatment of antipsychotics is the risk of development of adverse events, which has an influence on acute and long-term compliance. One of the possibilities of prevention of development of adverse events is an adequate dosage of this medication. The survey of factors, which are necessary to pay attention for choosing of the dose of antipsychotics, is presented in this article.

Keywords: antipsychotics, schizophrenia, dosage, D2 occupancy, compliance, adverse events

Published: February 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Racková S, Janů L. DOSING OF ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA. Psychiatr. praxi. 2006;7(6):268-271.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ahnag-Wong J, Zipursky RB, Beiser M, Bean G. Optimal haloperidol dosage for first-episode psychosis. Can J Psychiatry, 1999; 44: 164-167. Go to original source... Go to PubMed...
    2. Corrigan PW, Liberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry, 1990; 41: 1203-1211. Go to original source... Go to PubMed...
    3. García-Cabeza I, Gómez JC, Sakristán JA, Edgell E, Chavez MG. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry, 2001; 1: 7-14. Go to original source... Go to PubMed...
    4. Gerlach J. Improving Outcome in Schizophrenia: The Potential Importace of EPS and Neuroleptic Dysphoria. Ann Clin Psychiatry, 2002; 14 (1): 47-57. Go to original source...
    5. Haan L, Lavalaye J, Bruggen M, Nimwegen L, Booij J, Amelsvoort T, Linszen D. Subjective Experience and Dopamine D2 Receptor Occupancy in Patiens Treated With Antipsychotics: Clinical Implications. Can J Psychiatry, 2004; 49: 290-296. Go to original source... Go to PubMed...
    6. Haan L, Lavalaye J, Linszen D, Dingemans PMAJ, Booij J. Subjective Experience and Striatal Dopamine D2 Receptor Occupancy in Patiens with Schizophrenia Stabilized by Olanzapine or Risperidone. Am J Psychiatry, 2000; 157: 1019-020. Go to original source... Go to PubMed...
    7. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry, 2003; 27: 1081-1090. Go to original source... Go to PubMed...
    8. Kapur S, Roy P, Daskalakis J, Remington G, Zipursky R. Increased Dopamine D2 Receptor Occupancy and Elevated Prolactin Level Associated With Addition of Haloperidole to Clozapine. Am J Psychiatry, 2001; 158: 311-314. Go to original source... Go to PubMed...
    9. Kapur S, Seeman P. Does Fast Dissociation From the Dopamine D2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis. Am J Psychiatry, 2001; 158: 360-369. Go to original source... Go to PubMed...
    10. Kapur S, Zipursky RB, Remington B. Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia. Am J Psychiatry, 1999; 156: 286-293. Go to original source... Go to PubMed...
    11. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double Blind PET Study of First-Episode Schizophrenia. Am J Psychiatry, 2000; 157: 514-520. Go to original source... Go to PubMed...
    12. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S. 5-HT2 and D2 Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation. Am J Psychiatry, 1998; 155: 921-928. Go to original source... Go to PubMed...
    13. Kissling W, Leucht S. Results of treatment of schizophrenia: Is the glass half full or half empty? Int Clin Psychopharmacology, 1999; 14 (Suppl 3): S11-S14. Go to original source... Go to PubMed...
    14. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry, 1991; 48: 739-745. Go to original source... Go to PubMed...
    15. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry, 1999; 56: 241-247. Go to original source... Go to PubMed...
    16. Voruganti L, Awad AG. Is Neuroleptic Dysphoria a Variant of Drug-Induced Extrapyramidal Side Effects? Can J Psychiatry, 2004; 49: 285-289. Go to original source... Go to PubMed...
    17. Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology, 2004; 171 (2): 121-132. Go to original source... Go to PubMed...
    18. Zisook S, McAdams L, Kuck J, Hartus J, Bailey A, Patterson TL, Judd LL, Jeste DV. Depressive Symptoms in Schizophrenia. Am J Psychiatry, 1999; 156: 1736-1743. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.